Based in China, XWPharma is a startup. Brouky records 1 investor associated with the company.
XWPharma is a Wuhan-based biopharmaceutical company focused on discovery and development of CNS therapeutics for neurological and psychiatric disorders. Its lead program, XW10508, is a Phase 2 oral NMDA antagonist being developed for treatment-resistant depression.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.